Vertex Pharmaceuticals Inc. (VRTX)

177.40
NASDAQ : Health Technology
Prev Close 180.12
Day Low/High 176.71 / 180.14
52 Wk Low/High 136.50 / 183.39
Avg Volume 1.59M
Exchange NASDAQ
Shares Outstanding 254.83M
Market Cap 45.90B
EPS 1.10
P/E Ratio 209.44
Div & Yield N.A. (N.A)
ProQR Cystic Fibrosis Drug Passes First, Early Efficacy Test

ProQR Cystic Fibrosis Drug Passes First, Early Efficacy Test

The development of QR-010 is still early but Thursday's preliminary study results were encouraging enough to boost ProQR's stock price.

Vertex Presents Long-Term Data Demonstrating That ORKAMBI® (lumacaftor/ivacaftor) And KALYDECO® (ivacaftor) Show The Potential To Modify The Progression Of CF

Vertex Presents Long-Term Data Demonstrating That ORKAMBI® (lumacaftor/ivacaftor) And KALYDECO® (ivacaftor) Show The Potential To Modify The Progression Of CF

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the presentation of long-term data demonstrating that ORKAMBI ® (lumacaftor/ivacaftor) and KALYDECO ® (ivacaftor) show the potential to...

Vertex Pharma (VRTX) Stock Lower on Q3 Miss

Vertex Pharma (VRTX) Stock Lower on Q3 Miss

Vertex Pharma (VRTX) reported lower-than-expected results for the third quarter late yesterday.

Pardon Me, but I Have a Few Things to Say... Vertex, Biogen, Ariad, Sarepta

Pardon Me, but I Have a Few Things to Say... Vertex, Biogen, Ariad, Sarepta

More about Vertex's Debbie Downer gene, Biogen's Alzheimer's spin and Sarepta caught in drug launch purgatory.

Vertex Pharma Moves Next-Generation Cystic Fibrosis Drugs Into New Clinical Trials

Vertex Pharma Moves Next-Generation Cystic Fibrosis Drugs Into New Clinical Trials

Vertex hopes the new drugs will improve on the efficacy and tolerability of Orkambi, the first combination therapy approved for cystic fibrosis in 2015.

Vertex Reports Third Quarter 2016 Financial Results

Vertex Reports Third Quarter 2016 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended September 30, 2016 and reviewed recent progress with its approved and investigational cystic...

Table 1 (Graphic: Vertex)

Table 1 (Graphic: Vertex)

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the planned initiation of two Phase 2 studies to evaluate the next-generation correctors VX-440 and VX-152 in triple combination regimens with...

Illumina Leads Healthcare Selloff, Abbott and Zimmer Also Fall

Illumina Leads Healthcare Selloff, Abbott and Zimmer Also Fall

Illumina fell 24% on news that it was cutting revenue guidance.

Vertex To Announce Third Quarter 2016 Financial Results On October 25

Vertex To Announce Third Quarter 2016 Financial Results On October 25

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2016 financial results on Tuesday, October 25, 2016 after the financial markets close.

When Does Vertex Pharmaceuticals Become a Buy?

When Does Vertex Pharmaceuticals Become a Buy?

Vertex Pharmaceuticals shares are down 31% year to date. Investors are wondering if they should hang on, buy or wait.

Vertex To Present At Upcoming Investor Conferences

Vertex To Present At Upcoming Investor Conferences

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at The Morgan Stanley Global Healthcare Conference in New York, NY on Wednesday, September 14 th at 11:40 a.

Vertex Pharmaceuticals Takes Over #81 Spot From Starbucks

Vertex Pharmaceuticals Takes Over #81 Spot From Starbucks

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Vertex Pharmaceuticals, Inc. has taken over the #81 spot from Starbucks Corp.

Vertex Provides Update On Ongoing Phase 3 Program For VX-661 In Combination With Ivacaftor For The Treatment Of Cystic Fibrosis

Vertex Provides Update On Ongoing Phase 3 Program For VX-661 In Combination With Ivacaftor For The Treatment Of Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided an update on its ongoing Phase 3 development program of its investigational compound VX-661 in combination with ivacaftor, which includes four studies...

Listen Up and Pay Attention to the Utes

This is where a lot of money has been parked in the last year.

Could a Spin-off of its Hepatitis C Division be in Gilead's Future?

Could a Spin-off of its Hepatitis C Division be in Gilead's Future?

The company also could look to acquire a smaller biotech company, though likely not Medivation.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMOT, ANGI, CBT, ELY, FTAI, GNBC, LOGM, NCR, SIX, SKUL, SLAB, SNY, SONS, TRK, TRN, UFS, VRTX, WES, ZNGA Downgrades: AF, BA, TER, WEX Initiations: FSV Read on to get TheStreet Quant Ratings' detailed report:

Vertex Reports Second Quarter 2016 Financial Results

Vertex Reports Second Quarter 2016 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended June 30, 2016 and reviewed recent progress with its approved and investigational cystic fibrosis...

A 'Semi-Charmed' Kind of NXPI Call Spread

A 'Semi-Charmed' Kind of NXPI Call Spread

It might be best to make this a late-afternoon purchase.

Vertex To Announce Second Quarter 2016 Financial Results On July 27

Vertex To Announce Second Quarter 2016 Financial Results On July 27

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2016 financial results on Wednesday, July 27, 2016 after the financial markets close.

3 Stocks Pushing The Health Care Sector Lower

3 Stocks Pushing The Health Care Sector Lower

TheStreet highlights 3 stocks pushing the health care sector lower today.

Wall Street Closes Higher as Fed Doves Make Case for Waiting on Rates

Wall Street Closes Higher as Fed Doves Make Case for Waiting on Rates

A dovish Federal Reserve in June pushes equities, crude to close around session highs.

Stocks Add to Gains as Fed Stresses Prudence in Policy-Making

Stocks Add to Gains as Fed Stresses Prudence in Policy-Making

Stocks add to gains by late afternoon Wednesday after the Federal Reserve's June meeting minutes confirm members' prudent approach to monetary policy.

Vertex And Moderna Establish Exclusive Collaboration To Discover And Develop MRNA Therapeutics™ For Cystic Fibrosis

Vertex And Moderna Establish Exclusive Collaboration To Discover And Develop MRNA Therapeutics™ For Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Moderna Therapeutics today announced that the two companies have entered into an exclusive research collaboration and licensing agreement aimed at the discovery...

Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here

Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

The New #41 Most Shorted Nasdaq 100 Component: Vertex Pharmaceuticals

The New #41 Most Shorted Nasdaq 100 Component: Vertex Pharmaceuticals

The most recent short interest data has been released for the 06/15/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Vertex Announces Presentations Of Data For KALYDECO® (ivacaftor) And ORKAMBI® (lumacaftor/ivacaftor) At European Cystic Fibrosis Society (ECFS) Conference

Vertex Announces Presentations Of Data For KALYDECO® (ivacaftor) And ORKAMBI® (lumacaftor/ivacaftor) At European Cystic Fibrosis Society (ECFS) Conference

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced presentations of KALYDECO ® (ivacaftor) and ORKAMBI ® (lumacaftor/ivacaftor) data at the 39 th European Cystic Fibrosis Society (ECFS)...

Biotech Stock Mailbag: Sarepta! Always More Sarepta. And Gilead, Too

Biotech Stock Mailbag: Sarepta! Always More Sarepta. And Gilead, Too

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

3 Stocks Pulling The Health Care Sector Downward

3 Stocks Pulling The Health Care Sector Downward

TheStreet highlights 3 stocks pushing the health care sector lower today.

Vertex To Present At The Goldman Sachs Healthcare Conference On June 7

Vertex To Present At The Goldman Sachs Healthcare Conference On June 7

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Goldman Sachs Healthcare Conference in Rancho Palos Verde, CA on Tuesday, June 7 th at 1:40 p.

TheStreet Quant Rating: B- (Buy)